Clinical trial · Observational
Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC
NCT04922073CI-TRIAL-00053548unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to assess the practical usability of EGFR mutation detection in ctDNA from early NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Performance of the EGFR assay
- timeFrame
- Immediately before the surgery
- description
- ADPS EGFR Mutation Test using plasma sample from clinical stage IB-IIIA NSCLC patients (reference: EGFR assay in tissue specimen)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with clinical stage IB to IIIA Non-small Cell Lung Cancer * Patients with resectable lung cancer * One of followings: 1) Never-smokers or ex-smokers who quit 10 years ago, 2) Female 3) Subsolid nodule in chest CT 4) Biopsy-proven adenocarcinoma Exclusion Criteria: * Patients with metastatic lung cancer (Stage IIIB-IV) * Patients who underwent chemotherapy or radiotherapy * Patients with other malignancies
References
Publications (0)
Data not yet available
No reference posted for this study.